StreetInsider.com News Articles

BioAge Labs begins Phase 2 trial of NLRP3 inhibitor BGE-102

Tue, 16 Jun 2026 08:00:44 -0400

BioAge Labs, Inc. (NASDAQ: BIOA) announced that the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept clinical trial evaluating BGE-102, an oral small molecule NLRP3 inhibitor, in patients at elevated cardiovascular risk.

The randomized, double-blind, placebo-controlled trial will enroll approximately 160 adults with obesity, elevated systemic inflammation as measured by high-sensitivity C-reactive protein (hsCRP) above 3 mg/L, and at least one additional cardiovascular risk factor. Participants will be assigned to one of four arms: placebo or BGE-102 at 30 mg, 60 mg, or 90 mg once daily, each for 12 weeks.

The primary endpoint is percent change from baseline

BioAge Labs begins Phase 2 trial of NLRP3 inhibitor BGE-102

Tue, 16 Jun 2026 08:00:44 -0400

The primary endpoint is percent change from baseline

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Tue, 16 Jun 2026 08:00:00 -0400

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors

Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3

Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels

Topline data anticipated in the second half of 2026

EMERYVILLE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA)

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Tue, 16 Jun 2026 08:00:00 -0400

Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3

Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels

Topline data anticipated in the second half of 2026

EMERYVILLE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA)

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Tue, 16 Jun 2026 08:00:00 -0400

Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3

Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels

Topline data anticipated in the second half of 2026

EMERYVILLE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA)

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Tue, 16 Jun 2026 08:00:00 -0400

Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3

Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels

Topline data anticipated in the second half of 2026

EMERYVILLE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA)

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Pande Vijay Satyanand

Fri, 12 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26641509.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Pande Vijay Satyanand

Fri, 12 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26641509.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Hemrajani Rekha

Fri, 12 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260612/26641480.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Hemrajani Rekha

Fri, 12 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260612/26641480.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: HEALY JAMES

Fri, 12 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260612/26641456.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: HEALY JAMES

Fri, 12 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260612/26641456.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: ENRIGHT PATRICK G

Fri, 12 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260612/26641443.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: ENRIGHT PATRICK G

Fri, 12 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260612/26641443.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Davidson Michael H.

Fri, 12 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260612/26641425.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Davidson Michael H.

Fri, 12 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260612/26641425.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: GARNIER JEAN PIERRE

Fri, 12 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260612/26641320.html

Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: GARNIER JEAN PIERRE

Fri, 12 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260612/26641320.html

Form 8-K BioAge Labs, Inc. For: Jun 10

Fri, 12 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260612/26638392.html

Form 8-K BioAge Labs, Inc. For: Jun 10

Fri, 12 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260612/26638392.html

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026